司来吉兰与普拉克索分别辅助多巴丝肼片治疗中晚期帕金森病的效果对比

Abstract
Figure/Table
References (17)
Related Citation (3)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the effect of Selegiline and Pramipexole respectively assisting on Levodopa and Benserazide Tablets in the treatment of middle and advanced Parkinson′s disease.Methods The clinical data of 50 patients with Parkinson′s disease admitted to our hospital from July 2014 to June 2017 were analyzed.According to different medication regimens，they were equally divided into control group （Selegiline combined with Levodopa and Benserazide Tablets）and observation group （Pramipexole combined with Levodopa and Benserazide Tablets），25 cases in each group.The unified parkinson′s disease rating scale （UPDRS）score and the Hamilton depression scale （HAMD）score before and after treatment were observed.The clinical effect and incidence of adverse reactions of the two groups were observed.Results The differences of UPDRS score and HAMD score between the two groups before treatment was not statistically significant （P＞0.05）.After treatment，the UPDRS score and HAMD score of the two groups were both lower than those before treatment（P＜0.05）.The UPDRS score and HAMD score of the observation group after treatment were both lower comarped with those in the control group （P＜0.05）.The total clinical effectiveness rate was higher in the observation group than that in the control group with statistical significance （P＜0.05）.There was no significant difference in the total incidence of adverse reactions between the two groups （P＞0.05）.Conclusion For patients with middle and advanced Parkinson′s disease，the UPDRS score and the HAMD score are markedly improved with a better effect in Pramipexole combined with Levodopa and Benserazide Tablets compared with Selegiline combined with Levodopa and Benserazide Tablets.

Key words： Selegiline Pramipexole Levodopa and Benserazide Tablets Middle and advanced Parkinson&prime s disease

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I4/80

［1］	潘可达，陈为安，方慧，等.盐酸多奈哌齐片联合司来吉兰片治疗帕金森病的临床研究［J］.中国临床药理学杂志，2017，33（8）：690-693.
［2］	Hsieh TH，Huang YZ，Rotenberg A，et al.Functional dopaminergic neurons in substantia nigra are required for transcranial magnetic stimulation-induced motor plasticity［J］.Cereb Cortex，2015，25（7）：1806-1814.
［3］	莫肇.脑蛋白水解物联合美多芭治疗帕金森病的临床疗效评价［J］.现代医院，2017，17（4）：564-565.
［4］	Sayin S，Cakmur R，Yener GG，et al.Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson′s disease［J］.J Clin Neurosci，2014，21（8）：1373-1376.
［5］	孙强.司来吉兰与左旋多巴联用治疗帕金森病运动障碍的临床观察［J］.解放军预防医学杂志，2016，34（S1）：7.
［6］	中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病的诊断标准（2016 版）［J］.中华神经科杂志，2016，49（4）：268-271.
［7］	印美财.司来吉兰与左旋多巴联用治疗帕金森病运动障碍的临床观察［J］.中西医结合心血管病杂志，2017，5（20）：162-163.
［8］	Filipovic SR，Rothwell JC，Bhatia K.Low-frequency repetitive transcranial magnetic stimulation and off phase motor symptoms in Parkinson′s disease［J］.J Neurol Sci，2010，291（1-2）：1-4.
［9］	Bech P，Gram LF，Dein E，et al.Quantitative rating of depressive states［J］.Acta Psychiatr Scand，1975，51（3）：161.
［10］	Bech P，Allerup P，Gram LF，et al.The Hamilton depression scale［J］.Acta Psychiatr Scand，1981，63（3）：290-299.
［11］	任凤飞.美多巴联合盐酸司来吉兰治疗帕金森病的临床分析［J］.中西医结合心血管病杂志，2017，5（27）：183-184.
［12］	Quinn L，Busse M，Bello-Haas VD.Management of upper extremity dysfunction in people with Parkinson disease and Huntington disease：facilitating outcom es across the disease lifespan［J］.J Hand Ther，2013，26（2）：148-155.
［13］	吕荣祥.美多巴联合普拉克索治疗帕金森病的有效性及安全性研究［J］.中国生化药物杂志，2014，34（3）：154-155，159.
［15］	敖文玲，胡明，方明，等.美多巴联合司来吉兰治疗帕金森病患者临床效果及安全性评价［J］.国际精神病学杂志，2016，43（4）：645-647.
［17］	中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南（第 3 版）［J］.中华神经科杂志，2014，47（6）：428-433.
［14］	Yan MH，Wang X，Zhu X.Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease［J］.Free Radical Biomed，2013，62（9）：90-101.
［16］	Goldstein DS.Biomarkers，mechanisms，and potential prevention of catecholam in eneuron loss in Parkinson diseas［J］.Adv Pharmcol，2013，68（9）：235-272.